Market Overview
The Global Tapentadol Market is estimated to reach at a Significant CAGR during the forecast period (2024-2031).
Tapentadol is a dual-mode analgesic that performs the actions of being a norepinephrine reuptake inhibitor and a mu-opioid receptor antagonist. Its analgesic properties come into effect within a few minutes of oral administration. Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain.
Market Summary
| Metrics | Details |
| Market CAGR | Prominent Growth |
| Segments Covered | By Product Type, By Application, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Market Dynamics
The tapentadol market growth is driven by the surge in prevalence of chronic disorders, such as chronic musculoskeletal pain, which is a key factor fueling the demand for tapentadol across the globe. Tapentadol is further used for the treatment of moderate to severe acute pain. In addition, a rise in the number of patients who have painful diabetic peripheral neuropathy significantly contributes toward the growth of the global tapentadol market.
The surge in prevalence of chronic disorders, such as chronic musculoskeletal pain, is expected to drive the growth in the forecast period
According to the data published by the Centers for Disease Control and Prevention (CDC), in 2019, 20.4% of adults had chronic pain, and 7.4% of adults had chronic pain that had limited work. Additionally, as per CDC, chronic pain increased with age, and the highest was reported in patients aged 65 years and above in the United States. Similarly, as per the Population Reference Bureau's Population Bulletin "Aging in the United States," the number of Americans aged 65 years and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. The high incidence of chronic pain among Americans and the growing geriatric population are expected to increase the demand for the tapentadol market over the forecast period.
Moreover, according to the Global Burden of Disease Study 2019, data showed that approximately 1.71 billion people globally have musculoskeletal conditions. While the prevalence of musculoskeletal conditions varies by age and diagnosis, people of all ages worldwide are affected. High-Income countries are the most affected in terms of people - 441 million, followed by countries in the WHO Western Pacific Region with 427 million and South-East Asia Region with 369 million.
Complications associated with the use of tapentadol is likely to hinder the market growth
Generally, tapentadol comes with its own set of contraindications, especially in treating people who have epilepsy or are susceptible to seizures. People suffering from a brain tumor, head injuries, or other conditions should avoid consuming it as it increases intracranial pressure. Its usage is discouraged for people with asthma as it boosts the risk of respiratory depression. Its consumption is also strictly prohibited for patients having biliary tract disease such as both acute and chronic pancreatitis as it may cause spasms of the sphincter of Oddi.
Besides this, tapentadol cannot be used for people suffering from severe liver diseases and should be carefully administered to moderate liver disease. Moreover, it is not recommended for treatment of women during and immediately before labor and delivery.
COVID-19 Impact Analysis on Market
Since the outbreak of the COVID-19 virus in 2019 December, over 100 countries across the world have been affected, and the World Health Organization has announced it a public health emergency. According to the World Health Organization report, Coronavirus (COVID-19) has infected more than 143 million individuals worldwide as of April 21, 2021.
The disruption in the supply chain due to the restrictions on transportation has led to several challenges faced by the manufacturers of tapentadol for procuring the raw materials, which led to a lowering of production rate, thereby affecting the global market.
Market Segmentation Analysis
The Tapentadol 100 mg segment is expected to hold the largest share in this market segment
Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain. It is available in the U.S. in extended-release formulations under the branded name Nucynta ER from Janssen Pharmaceuticals.
Tapentadol is often used to ease the pain, which cannot be managed with other types of analgesics. Its formulation is provided in 100 mg (red/orange), 75 mg (orange), and 50 mg (yellow) tablets to be used once every five hours as needed to control pain. Tapentadol in 100 mg is mostly used as the first line of therapy. It is currently not recommended to exceed more than 700 mg/day of tapentadol on the first day of therapy and no more than 600 mg/day on subsequent days, with most patients, taking 50 to 100 mg every 4 to 6 hr as needed for pain. Tapentadol is a Schedule II controlled substance with an abuse potential similar to other potent opioid analgesics. During clinical trials, immediate-release tapentadol 100 mg provided analgesic efficacy equivalent to that produced by 15 mg of immediate-release oxycodone. But the incidence of side effects associated with tapentadol is less than oxycodone. Thus, the demand for tapentadol 100 mg is increasing in patients with acute to severe musculoskeletal pain.
Market Geographical Share
North America region holds the largest market share of the global tapentadol market
North America is the leading tapentadol market, followed by Europe and the Asia Pacific. The demand for tapentadol is exceptionally high in the U.S., owing to a higher percentage of the elderly population, a demographic that forms the leading consumer pool for tapentadol globally. For instance, according to the United Nations data of World Population Prospects for the year 2019, the number of people over 65 increases from 9% in 2019 to more than 16% of the total world’s population by 2050. The number of persons aged 80 years or over is also projected to triple, from 143 million in 2019 to 426 million in 2050. Thus, the rise in the volume of the patient pool results in a higher demand for the tapentadol market fueling the global market growth over the forecast period.
Moreover, the growing number of prescriptions in the US also driving the tapentadol market. For instance, according to the US Medicaid Prescriptions, around 78458 prescriptions were prescribed.
Market Companies and Competitive Landscape
The global tapentadol market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson Services, Inc, Grünenthal Ltd, UK. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Key Companies to Watch
Grünenthal Ltd
Overview: Grünenthal Ltd, is an independent, family-owned company with headquarters in Aachen, Germany. Its operations are present in 29 countries with affiliates in Europe, Latin America and the USA. Their products are sold in more than 100 countries and with around 4,700 employees worldwide.
Product Portfolio: The Company’s portfolio comprised of include pain management drugs.
Product: In 2014, Palexia (tapentadol tablets and oral solution) & in 2011 Palexia SR (tapentadol prolonged release) are launched by Grunenthal.
Key Developments:
On 2, August 2021, Grünenthal initiated a recall of all batches of Palexia 20 mg/ml oral solution and Palexia 4 mg/ml oral solution and halted production until further notice due to a bacterial contamination issue. Palexia® tablets are not affected by the contamination and are not being recalled.
Why Purchase the Report?
- Visualize the composition of the tapentadol market segmentation by product type, application, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the tapentadol market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of tapentadol market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global tapentadol market report would provide access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
